Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical leader founded in 1887, specializing in the discovery, development, and manufacturing of prescription medications. The company focuses on high-impact therapeutic areas, including oncology, cardiovascular disease, immunoscience, and virology. By leveraging advanced research and development, Bristol-Myers Squibb delivers innovative treatments for complex conditions such as HIV and various cancers. The organization maintains a robust portfolio of therapies, including immuno-oncology solutions like Opdivo and Orencia, which address significant unmet medical needs.

Operating with over 10,000 employees across 51 global locations, the company maintains a sophisticated operational footprint. Meet Bristol-Myers Squibb's team to understand the leadership driving these scientific advancements. Learn about Bristol-Myers Squibb's global headquarters in Princeton, New Jersey, which serves as the central hub for its international operations. The company utilizes a collaborative model, engaging in strategic research partnerships and alliances to accelerate the translation of scientific breakthroughs into clinical practice. This integrated approach ensures efficient distribution and patient access to critical medications worldwide.

Bristol-Myers Squibb, traded on the NYSE under the ticker BMY, demonstrates strong market performance within the competitive pharmaceutical landscape. With annual revenue reaching $48.5B, the company remains a key player alongside major competitors like Novartis, AbbVie, and Pfizer. Explore financial highlights to review detailed metrics, funding history, and fiscal performance. The firm’s commitment to sustained R&D investment and its strategic focus on high-growth disease areas position it for continued leadership in the global healthcare sector.